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Background: Staphylococcus aureus is an opportunistic commensal bacterium that mostly colonizes the skin and
soft tissues. The pathogenicity of S. aureus is due to both its ability to resist antibiotics, and the production of
toxins. Here, we characterize a group of genes responsible for toxin production and antibiotic resistance of S. aureus
strains isolated from skin, soft tissue, and bone related infections.
Results: A total of 136 S. aureus strains were collected from five different types of infection: furuncles, pyomyositis,
abscesses, Buruli ulcers, and osteomyelitis, from hospital admissions and out-patients in Benin. All strains were
resistant to benzyl penicillin, while 25% were resistant to methicillin, and all showed sensitivity to vancomycin.
Panton-Valentine leukocidin (PVL) was the most commonly produced virulence factor (70%), followed by
staphylococcal enterotoxin B (44%). Exfoliative toxin B was produced by 1.3% of the strains, and was only found in
isolates from Buruli ulcers. The tsst-1, sec, and seh genes were rarely detected (≤1%).
Conclusions: This study provides new insight into the prevalence of toxin and antibiotic resistance genes in
S. aureus strains responsible for skin, soft tissue, and bone infections. Our results showed that PVL was strongly
associated with pyomyositis and osteomyelitis, and that there is a high prevalence of PVL-MRSA skin infections
in Benin.
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Staphylococcus aureus is an opportunistic pathogen that
mainly colonizes the nares and skin of up to 80% of the
population [1]. S. aureus is a Gram-positive cocci that is
frequently isolated in hospitals, and is responsible for di-
verse infections and toxicoses [2]. S. aureus is the most
common cause of skin and soft-tissue infections (such as
impetigo, furunculosis, and abscess), as well as systemic
infections (such as pneumonia and endocarditis) [3].
The threat of S. aureus is not only due to its distribution* Correspondence: laminesaid@yahoo.fr
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reproduction in any medium, provided the orand pathogenicity [4,5], but also because of its ability to
overcome antimicrobial agents [6-8].
Virulence factors produced by S. aureus render this or-
ganism highly pathogenic. The known virulence factors
include exotoxins, such as exfoliative toxins (ETs), along
with toxic shock syndrome toxin-1 (TSST-1), staphylo-
coccal enterotoxins (SEs), leukocidins (Panton-Valentine
leukocidin; PVL, LukE/D), and hemolysins (α, β, γ, δ)
[9]. Enterotoxins often cause food poisoning [10], while
ETs (also called epidermolysins) act on the skin [11].
Among the leukocidins, PVL is an extracellular protein
consisting of two subunits, F and S, which act in concert
and have leucocidal and dermonecrotic functions. The
PVL toxin targets the outer membrane of polymorpho-
nuclear cells, monocytes, and macrophages [12-15]. S. aureus. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2180/13/188strains that are positive for PVL are usually associated with
skin and soft-tissue infections, and were first isolated in the
1960s [16-19]. PVL-positive strains are particularly associated
with furuncles, accounting for 96% of cases [11,17,20], and
approximately 90% of PVL-positive S. aureus strains were
originally isolated from furuncles. PVL has also been asso-
ciated with severe infections, including necrotizing pneu-
monia [19,21-24], osteomyelitis [25], and even cases of
purpura fulminans [26]. PVL toxin was recently identified
in Lemierre’s syndrome [27], and in a case of Fournier’s
gangrene [28]. PVL has also been associated with
community-acquired necrotizing and hemorrhagic pulmo-
nary infections affecting previously healthy children and
young adults [22,29].
Several antibiotics were routinely used in the treatment
of S. aureus infections, contributing to the emergence of
antibiotic-resistant strains. Widespread resistance severely
complicates management of S. aureus infections. S. aureus
strains that are resistant to methicillin (methicillin-resistant
S. aureus, MRSA) are pervasive in the hospital environ-
ment, and have recently also caused a global epidemic of
community-associated S. aureus (CA-MRSA) infections
[30]. The changing trend of MRSA epidemiology, showed
the use of PVL locus detection as a marker of CA-MRSA
isolates, alongside with non multiresistant pattern and
SCCmec type IV or V [31]. Vancomycin has been used
successfully for over 50 years for the treatment of S. aureus
infections, particularly those caused by MRSA strains [32].
However, vancomycin-resistant S. aureus (VRSA) and
vancomycin-intermediate (VISA) strains have been
reported, three decades after the introduction of vancomycin
[33]. The presence of resistance genes may also affect toxin
production.
The production of multiple virulence factors, as well
as the presence of antibiotic resistance genes, makes S.
aureus a highly pathogenic microorganism. The objec-
tive of this work was to study the susceptibility profile
and toxin production of S. aureus strains isolated from
various skin, soft tissue, and bone infections.B
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Figure 1 Global Staphylococcus aureus strains isolated from
primary and secondary infections resistance profile to 22
antibiotics. Benzyl penicillin (BP), oxacillin (Ox), cefoxitin screen
(Cef), gentamicin (Gen), tobramycin (Tob), kanamycin (Kan),
vancomycin (Van), teicoplanin (Tei), fusidic acid (FA), fosfomycin
(Fos), rifampicin (Rif), trimethopim/sulfamethoxazole (T/Sul),
erythromycin (Ery), lincomycin (Lin), pristinamycin (Pri), linezolid
(Line), tetracyclin (Tet).Results
Prevalence of S. aureus strains according to the sample
origin
Using standard microbiological methods for identifica-
tion of microorganisms; a total of 136 strains of S. aur-
eus were collected during this study. The proportions of
the strains varied depending on the five types of infec-
tion: furuncle, osteomyelitis, pyomyositis, abscess, and
Buruli ulcer. Almost 37% (50/136) of the collected
strains originated from abscesses, followed by strains
isolated from pyomyositis patients (27%, 37/136), furun-
cles (14%, 19/136), Buruli ulcers (12%, 16/136), and
osteomyelitis cases (10%, 14/136).Susceptibility to antibiotics
There was a wide range in the susceptibility of the isolates
to the various antibiotics examined. All of the strains were
resistant to benzyl penicillin, while other antibiotics
(vancomycin, fusidic acid, fosfomycin, and linezolid) were
active against some of the strains (Figure 1).
There was no significant difference in the antibiotic re-
sistance of the strains based on their origin (Figure 2). S.
aureus strains originating from pyomyositis (Figure 2a),
furuncles (Figure 2b) and osteomyelitis cases (Figure 2c)
were resistant to 4/17 tested antibiotics (benzyl penicillin,
rifampincin, tetracycline, and trimetroprim/sulfametho-
xazol), while strains originating from abscesses and Buruli
ulcer were strongly resistant to respectively 13/17 and 7/
17 of the tested antibiotics (Figure 2d, e). Of the 136 iso-
lated S. aureus strains, 34 (25%) were resistant to oxacillin
(MRSA), while none of the strains showed resistance to
vancomycin (VRSA). The oxacillin-resistant strains were
all isolated from abscesses and Buruli ulcers.
Toxins production and/or presence of their encoding genes
There was a significant difference in the production
and/or the presence of genes encoding the 12 toxins (p
< 0.0001). Thus, a significant number of strains (70.0%)
were capable of producing PVL, followed by the produc-
tion of staphylococcal enterotoxin B (SEB) (44.3%). None
of the strains contained the genes responsible for ex-
foliative toxin B (ETB) or staphylococcal enterotoxin D
(SED) production, while the ability to produce staphylo-
coccal enterotoxins C and E (SEC, SEE), as well as the
toxic shock syndrome toxin (TSST), was detected in
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d. Osteomyelitis
B
P
O
x
C
ef
G
en
T
ob
K
an
V
an T
ei FA Fo
s
R
if
T
/S
ul
E
ry L
in Pr
i
L
in
e
T
et
0
20
40
60
80
100
Antibiotics
P
e
rc
e
n
ta
g
e
 o
f 
te
st
e
d
st
ra
in
s 
(%
)
e. Buruli ulcer 
Figure 2 Staphylococcus aureus strains resistance profile to 22 antibiotics according to their origin. Benzyl penicillin (BP), oxacillin (Ox),
cefoxitin screen (Cef), gentamicin (Gen), tobramycin (Tob), kanamycin (Kan), vancomycin (Van), teicoplanin (Tei), fusidic acid (FA), fosfomycin (Fos),
rifampicin (Rif), trimethopim/sulfamethoxazole (T/Sul), erythromycin (Ery), lincomycin (Lin), pristinamycin (Pri), linezolid (Line), tetracyclin (Tet).
Sina et al. BMC Microbiology 2013, 13:188 Page 3 of 9
http://www.biomedcentral.com/1471-2180/13/188<1% of strains (Figure 3). The observed difference was
related to the origin of the S. aureus strains. PVL was
the most commonly produced toxin, regardless of the
origin of the strains (Figure 4). PVL toxin was particu-
larly prevalent in strains isolated from furuncles (89.5%)PV
L
 
E
T
A
 
E
T
B
 
SE
A
 
SE
B
 
SE
C
 
S
E
D
S
E
E
S
E
G
S
E
H
S
E
I
T
S
S
T
0
20
40
60
80
100
Toxins of S. aureus
P
er
ce
n
ta
g
e 
o
f 
te
st
ed
st
ra
in
s 
(%
)
***
Figure 3 Toxins production by the Staphylococcus aureus
strains isolated from primary and secondary infections.
PVL: Panton-Valentine Leukocidin; ETA: Exfoliative Toxin A;
ETB: Exfoliative Toxin B; SEA: staphylococcal enterotoxin A;
SEB: staphylococcal enterotoxin B; SEC: staphylococcal enterotoxin C;
SED: staphylococcal enterotoxin D; SEE: staphylococcal enterotoxin E;
SEG: staphylococcal enterotoxin G; SEH: staphylococcal enterotoxin H;
SEI: staphylococcal enterotoxin I; TSST: Toxic-shock syndrome Toxin.
Means ± standard deviations (SD) for three experiments are given.
***: p˂0.0001.and pymyositis patients (89.2%). Other toxins were pro-
duced in various proportions depending on the origin of
the strain (p < 0.0001). There was a significant difference
in the detection of genes encoding toxins in MRSA
strains (Figure 5).
Discussion
The S. aureus stains analyzed in this study displayed a
wide range of sensitivity to the 17 tested antibiotics. Gen-
erally, benzyl penicillin was not efficient in controlling the
strains (Figure 1). This is consistent with previous reports
showing high rates of S. aureus resistance (>90%) to ben-
zyl penicillin [34,35], suggesting that this antibiotic, one of
the first to be introduced, is no longer effective against S.
aureus [36]. A very high proportion of strains showed re-
sistance to rifampicin (67%), tetracycline (60%), and
trimetroprim/sulfamethoxazol (57%). This finding is con-
sistent with previous studies performed in Africa [37-40].
The high proportion of strains showing resistance to peni-
cillin and three other antibiotics may be explained by the
practice of patient self-medication in Benin, and by the
availability and low price of the antibiotics. These antibi-
otics can be bought without prescription, especially in de-
veloping countries. In our in vitro study, 4/17 tested
antibiotics (vancomycin, fusidic acid, fosfomycin, and
linezolid) were effective against all the S. aureus strains.
The collection of strains isolated from abscesses was
sensitive to only four of the 17 tested antibiotics. How-
ever, strains isolated from furuncles (Figure 2b) and
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Figure 4 Specificity of the toxins production by the S. aureus strains isolated from primary and secondary infections. PVL: Panton-
Valentine Leukocidin; ETA: Exfoliative Toxin A; ETB: Exfoliative Toxin B; SEA: staphylococcal enterotoxin A; SEB: staphylococcal enterotoxin B; SEC:
staphylococcal enterotoxin C; SED: staphylococcal enterotoxin D; SEE: staphylococcal enterotoxin E; SEG: staphylococcal enterotoxin G; SEH:
staphylococcal enterotoxin H; SEI: staphylococcal enterotoxin I; TSST: Toxic-shock syndrome Toxin. Means ± standard deviations (SD) for three
experiments are given.
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Figure 5 Effect of Methicillin resistance on the encoding toxins
genes presence. PVL: Panton-Valentine Leukocidin; ETA: Exfoliative
Toxin A; ETB: Exfoliative Toxin B; SEA: staphylococcal enterotoxin A;
SEB: staphylococcal enterotoxin B; SEC: staphylococcal enterotoxin
C; SED: staphylococcal enterotoxin D; SEE: staphylococcal
enterotoxin E; SEG: staphylococcal enterotoxin G; SEH:
staphylococcal enterotoxin H; SEI: staphylococcal enterotoxin I;
TSST: Toxic-shock syndrome Toxin. Means ± standard deviations (SD)
for three experiments are given. ***: P˂0.001; the other differences
were not statistically significant (P˃0.05).
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http://www.biomedcentral.com/1471-2180/13/188osteomyelitis patients (Figure 2d) were sensitive to 13
antibiotics (Figure 2). This result can likely be attributed
to the origin of the strains. In our study, the samples
collected from furuncles and osteomyelitis patients were
from an extra-hospital community origin. Indeed, the
selection pressure observed when using antibiotics in
a hospital environment causes nosocomial strains to
develop multi-resistance, in contrast to strains of com-
munity origin.
Of the 136 tested strains, 34 (25%) were resistant to
oxacillin. This proportion of resistant strains appears to
have increased steadily in Benin, compared with the
recorded resistance rate of 11.6% in 1999 [40]. However,
the overall proportion of oxacillin-resistant strains in
Benin is still low compared to surrounding countries
[41], even though methicillin is the preferred antibiotic
for treatment of staphylococcal infections [42]. To effi-
ciently control MRSA, vancomycin is recommended
[43], and in our study we observed no resistance to
vancomycin. Fortunately, vancomycin remains active
against methicillin resistant strains of S. aureus.
In the current study of S. aureus strains isolated from
skin, soft tissue, and bone related infections, PVL was
the most prevalent toxin in our collection (70.0% of
strains), followed by SEB (44.3%), SEG (35.5%), SEA
(32.0%), SEH (28.8%), and SEI (28.9%). The genes encod-
ing ETB and SED were not detected in any of the
Sina et al. BMC Microbiology 2013, 13:188 Page 5 of 9
http://www.biomedcentral.com/1471-2180/13/188strains, while the SEE (0.8%), SEC (0.6%), and TSST
(1%) genes were detected, but at a very low rate (Figure 3).
This high detection frequency of the gene encoding
PVL (p < 0.0001) was observed throughout the ana-
lysis, regardless of the origin of the sample (Figure 4).
PVL appears to be a primordial toxin of S. aureus strains
associated with skin, soft tissue, and bone related infec-
tions. These results are lower than the 96% of PVL-
positive production strains we observed among S. aureus
isolated from furuncle [20]. But the prevalence of PVL-
positive S. aureus obtained in our study is higher than
the 52.1% observed in Nigeria [44] and in cape Verdes
Island [45]. The observe differences observed can be
explain by the fact that in our study, we use various
kind of strains. However, our result is close to the 72%
obtained in Algeria [46]. Then, comparing with the
other studies, we can say that the prevalence level of PVL
ocus varies with geographical location, and clinical spe-
cimen [47] In the clinical field, PVL-positive S. aureus
strains are more pathogenic than PVL-negative strains
[22]. This is explained by the fact that the lytic activity
of PVL directly affects monocytes, macrophages, poly-
nuclear neutrophils, and metamyelocytes, although
erythrocytes are not lysed by PVL [48]. PVL toxin is
known to have a cytolytic effect, and as such polynuclear
neutrophils were identified as important indicators of
staphylococcal virulence [16]. Moreover, the cytolytic ac-
tivity of PVL is observed at high toxin concentrations,
while apoptosis is observed at low concentrations [49].
Regarding the ETs, only the gene encoding epidermolysin
A (ETA) was detected, and in all cases the S. aureus strains
were isolated from Buruli ulcers (Figure 4e). Such specific
production of ETA by Buruli ulcers may be explained by
the fact that ETs are known to be serine active proteases,
with their activity highly specialized for desmoglein-1, an
important epidermal protein [50,51]. Therefore, the pro-
duction of ETA by S. aureus strains from Buruli ulcers indi-
cates a secondary role for S. aureus in the development of
these ulcers, which are predominantly caused by Mycobac-
terium ulcerans.
Of the eight genes encoding enterotoxins, three (SEC,
SED, and SEE) were not detected at all, while three
others (SEA, SEB, and SEH) were detected at various
proportions, regardless of the origin of the strains
(Figure 4). Based on the homology of their sequences, the
three detected enterotoxin genes belong to three differ-
ent groups [52]. This explains the diversity of entero-
toxins produced by S. aureus isolated from skin
infections. Those toxins associated with food poisoning
have antigenic and emetic activities [53-55]. The pres-
ence of enterotoxin genes in the strains isolated from
skin, soft tissue, and bone related infections may be
explained by human or environmental contamination,
through the presence of open wounds. Similarobservations are reported for TSST-1, which is the most
prevalent toxin in cases of food poisoning [56].
Our study revealed that resistance to methicillin nega-
tively correlates with toxin production (Figure 5). The dif-
ference in toxin production was extremely significant for
PVL and some enterotoxins (B, G, and I) (p < 0.0001), and
we observed that MSSA strains produced twice as many
toxins as MRSA strains. These results suggest that the iso-
lated strains were in majority Hospital acquired methicillin
resistance S. aureus (HA-MRSA) because the community-
acquired methicillin resistance S. aureus (CA-MRSA). In-
deed, these CA-MRSA have an SCCmec type IV cassette
conferring resistance to methicillin [57], and 77% of them
harbor genes for Panton- Valentine leukocidin (PVL)
[58,59]. In addition, the prevalence of the genes for some
toxins is higher in CA-MRSA than in HA-MRSA, sugges-
ting that strains circulating in the community are more
toxinogenic than hospital-associated strains [60]. Focusing
on the duality of the observed activity between the resist-
ance to methicillin and detection of the PVL-encoding
gene, we may deduce that the resistance gene has a repres-
sive activity against PVL. This observation was also made
by Baldwin and Lowe [61], and mostly relates to HA-
MRSA strains. In addition, we found that the presence of
the methicillin resistance gene negatively impacts the
expression of the gene encoding PVL. The emergence of
MRSA in the hospital acquired strains may be viewed as
disadvantageous in the selection of strains producing
toxins, notably PVL. Indeed, mecA-encoded methicillin
resistance involves β-lactamase production [62], which is
not favorable for bacterial development [63]. Although
community-acquired MRSA infections are increasingly
frequent, the use of alternative antibiotics, such as vanco-
mycin or ofloxacin/ciprofloxacin, is not appropriate be-
cause of the risk of the development of resistance to these
antibiotics. Vancomycin is usually not available because of
high costs and the necessity for assessing drug levels in
the blood. Studies on the use of vancomycin for prophy-
laxis in medical centers with high rates of MRSA show
that the use of this antibiotic is controversial in preventing
some infections.
Conclusions
Our study showed that for S. aureus strains isolated
from skin, soft tissue, and bone related infections, resist-
ance to antibiotics depends on the origin of the strain.
We attempted to perform a correlation analysis between
toxin production, resistance to antibiotics, and the origin
of samples. The S. aureus strains examined in this study
produced a variety of toxins, with PVL, one of the most
severe S. aureus toxins, being the most common
amongst all of the strains. Overall, it is desirable to inte-
grate to the current morphological and biochemical
diagnostic analysis with virulence factor screening to
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aureus. This integrated diagnostic strategy will help to
efficiently treat patients affected by pathogenic S. aureus
strains. This study concerning skin, soft tissue, and bone
related infections should be extended to include other
types of infections in Benin.
Methods
Ethics statement
Ethical clearance was obtained from the Ministry of
Public health of Benin Republic under protocol number:
2959/MSP/DC/SG/DRH/SPREA-05-2002. But it was
important to notice that, the strains were de-identified
and analyzed anonymously and the strains, not a human,
were studied.
Samples collection
Clinical Staphylococcus aureus samples were collected
from patients with skin, soft tissue at the National
University Hospital of Cotonou (Benin) for various bac-
teriological screenings in routine, from November 2009
to March 2011. The incidence of secondary infections in
Burili ulcer is unknown; antibiotics may be frequentlyTable 1 Primers sequences used in this study for the detectio
Primers Sequences
eta 5′-GCAGGTGTTGATTTAGCATT-3′
5′-AGATGTCCCTATTTTTGCTG-3′
etb 5′-ACCCCTGTTCCCTTATCATC-3′
5′-GTTTTTGGCTGCTTCTCTTG-3′
lpv 5′-AAAATGCCACTGTTATCCAGAGGTA-3′
5′-TTTGCAGCGTTTTGTTTTCG-3′
sea 5′-ATGGTTATCAATGTGCGGGTGIIIIICCAAACAAAAC-3′
5′-TGAATACTGTCCTTGAGCACCAIIIIIATCGTAATTAAC-3′
seb 5′-TGGTATGACATGATGCCTGCACIIIIIGATAAATTTGAC-3′
5′-AGGTACTCTATAAGTGCCTGCCTIIIIIACTAACTCTT-3′
sec 5′-GATGAAGTAGTTGATGTGTATGGATCIIIIIACTATGTAAAC-3′
5′-AGATTGGTCAAACTTATCGCCTGGIIIIIGCATCATATC-3′
sed 5′-CTGAATTAAGTAGTACCGCGCTIIIIIATATGAAAC-3′
5′-TCCTTTTGCAAATAGCGCCTTGIIIIIGCATCTAATTC-3′
see 5′-CTTACCGCCAAAGCTGTCG-3′
5′-GTCCACTTGTAAATGGTAGCGAGAA-3′
seg 5′-AATTATGTGAATGCTCAACCCGAT-3′
5′-CTTTAGTGAGCCAGTGTCTTGCTTTG-3′
seh 5′- CATCTACCCAAACATTAGCACC-3′
5′-AGAAATCAAGGTGATAGTGGCAA-3′
sei 5′-AGGCGTCACAGATAAAAACCTACCIIIIICAAATCAACTC-3′
5′-ACAAGGACCATTATAATCAATGCCIIIIITATCCAGTTTC-3′
tsst-1 5′-ACCCCTGCCTTTCCATCATC-3′
5′-TTTTCAGTATTTGTAACGCC-3′prescribed for this indication. It is equally unknown
which bacteria these antibiotics should target and what
the sensitivity of these bacteria is. So the samples
from Burili ulcer were screened for S. aureus. Theses
samples were carried out during a prospective study
made in a village of Lalo in Benin. Osteomyelitis and
pyomyositis samples were collected during a prospec-
tive study made in a Hlagba Ouassa village in Benin.
So these strains are considered as community strains
and the others sample were isolated in hospital as
stated previously.
S. aureus’ identification
Standard microbiological methods for identification of
microorganisms were applied. All swabs were inoculated
onto mannitol salt agar, incubated at 37°C and inspected
visually for three days. Any suspected colony was
subcultured on tryptic soy agar (bioMérieux) and identi-
fied by subsequent Gram staining, catalase test and
Slidex Staph Plus (bioMérieux) and the coagulase test
with the rabbit plasma [64]. Bacterial identification was
performed by colony isolation on sheep blood agar
plates and the automated Vitek 2 system.n of genes encoding toxins
Polarity Expected fragment (base pair) Accession N°
Sens 93 A8658-043
Antisens A8658-044
Sens 226 A8659-036
Antisens A8659-037
Sens 433 A8658-029
Antisens A8658-030
Sens 520 A8658-031
Antisens A8658-032
Sens 163 A8658-033
Antisens A8658-034
Sens 283 A8658-035
Antisens A8658-036
Sens 384 A8658-037
Antisens A8658-038
Sens 159 A8658-039
Antisens A8658-040
Sens 408 HA01804615
Antisens HA01804616
Sens 222 HA01804617
Antisens HA01804618
Sens 454 HA01804619
Antisens HA01804620
Sens 209 A8658-041
Antisens A8658-042
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Antimicrobial susceptibility was determined by the disc
diffusion method of Kirby-Bauer on agar Mueller-Hinton
(bioMérieux, Marcy l'Etoile, France) as recommended by
the Antibiogram Committee of the French Microbiology
Society (CASFM) [65]. After 24 h at 37°C, the zone of in-
hibition was measured. Susceptibility to vancomycin was
confirmed by broth microdilution methodology as de-
scribed by the Clinical and Laboratory Standards Institute
(CLSI) [66]. For susceptibility to oxacillin, an inoculum of
107 CFU/ml was prepared and the plate was incubated at
37°C for 24 hours on Mueller-Hinton agar + 2% NaCl.
Antibiotic disks were obtained from Biorad, Marne la
Coquette, France.
The 17 tested antibiotics were: benzyl penicillin (10
UI), oxacillin (5 μg), cefoxitin screen (30 μg), gentamicin
(10 UI), tobramycin (10 μg), kanamycin (30 μg), vanco-
mycin (30 μg), teicoplanin (30 μg), fusidic acid (10 μg),
fosfomycin (50 μg), rifampicin (30 μg), trimethoprim/
sulfamethoxazole (1.25/23.75 μg), erythromycin (15 μg),
lincomycin (30 μg), pristinamycin (15 μg), linezolid (30
μg) and tetracyclin (30 UI).
Toxin detection
Phenotypic detection of toxins
For the phenotypic detection of toxins radial gel immu-
nodiffusion was performed. The production of Panton-
Valentine Leukocidin (PVL) and epidermolysins A (ETA)
and B (ETB) were evidenced from culture supernatants
after 18 h of growth in Yeast Casamino-acid Pyruvate
(YCP) medium [67] by radial gel immunodiffusion in
0.6% (wt/vol) agarose with component-specific rabbit
polyclonal and affinity-purified antibodies [68,69].
Genotype detection of toxins
Presence of genes encoding for the 12 toxins, for which
we don’t have antibody, was detected by Multiplex PCR
using specific primers (Table 1) previously used for [70].
Then, the genes encoding for enterotoxins A (sea), B
(seb), C (sec), D (sed), E (see), G (seg), H (seh), I (sei) and
tsst were analyzed. Additionally, genes encoding PVL,
ETA and ETB were also detected. Briefly, total DNA was
purified using QIAamp® DNA Mini Kit (Qiagen, GmbH,
Germany) with a Gene Amp® PCR System 9700 (Perkin-
Elmer, Norwalk, USA) and amplified in a total volume of
50 μl containing 25 pmoles of each primer, 50 ng of total
DNA, 1.5 mM MgCl2, 200 μM of dNTP mixture, 1×
PCR reaction Buffer and 5 units of Taq™ DNA polymer-
ase (Invitogen™). The thermal cycling conditions in-
cluded an initial denaturation step (2 min at 92°C)
followed by 35 cycles of amplification comprising three
steps: 2 min denaturation for 92°C, 1 min annealing at
50°C, 2 min extension at 72°C. The reaction was termi-
nated with 3 min extension at 72°C. PCR products wereanalysed by electrophoresis through 1.4% (wt/vol) agar-
ose gel (Euromedex, Mundolsheim, France).
Staphylococcal enterotoxins production (SEA, SEB, SEC,
SED, SEE, SEG, SEH, SEI) by Bio-Plex Assay (xMAP
Multiplex assay)
The centrifuged supernatant (3ml) of S. aureus grown
on BHI at 37°C (night) was recovered and diluted ½ in
TBS-Tween20-IgG rabbit nonspecific at 100μg/mL, and
incubated for 30 min at room temperature. The Bio-Plex
assays consisted of three incubation steps that were
performed into flat-bottom Multiscreen microplates
(pores diameter = 1.2 μm, Millipore) according to the
previous describe method [71]. Any steps were separated
by three washes into TBS-Tween 20.
Statistical analysis
Microsoft Excel Spreadsheet has been used for data pro-
cessing. For comparison tests of positive isolates of each
patient group, we used the Student T test, and the
Fischer’s test for lower number series (GraphPad Prism
5). P < 0.05 was considered statistically significant.
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